Back to Search Start Over

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.

Authors :
Wasserman, Richard
Melamed, Isaac
Stein, Mark
Engl, Werner
Sharkhawy, Marlies
Leibl, Heinz
Puck, Jennifer
Rubinstein, Arye
Kobrynski, Lisa
Gupta, Sudhir
Grant, Andrew
Ratnayake, Anoshie
Richmond, Wendell
Church, Joseph
Yel, Leman
Gelmont, David
Source :
Journal of Clinical Immunology; Aug2016, Vol. 36 Issue 6, p571-582, 12p
Publication Year :
2016

Abstract

Purpose: Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, prospective, non-controlled, multi-center studies. Methods: Subjects >4 years of age received SC IgG replacement at a weekly dose equivalent of 108 % of their previous intravenous (IV) dose, facilitated by prior injection of 75 U/g IgG of rHuPH20. Starting with weekly SC infusions, the interval was increased (ramped-up) to a 3- or 4-week schedule. Results: Eighty-three subjects (24 < 18 years; 59 ≥ 18 years) received 2729 infusions (excluding ramp-up) at a mean dose of 0.155 g/kg/week in the pivotal and 0.156 g/kg/week in the extension study. IGHy exposure exceeded 30 months in 48 subjects. During 187.7 subject-years of IGHy exposure, 2005 adverse events (AEs) (10.68 per subject-year) occurred. The rate of related systemic AEs during consecutive 1-year periods remained low; the rate of related local AEs decreased from 3.68/subject-year in months 1-12 to approximately 1.50/subject-year after 30 months of treatment. Fifteen subjects transiently developed anti-rHuPH20 binding antibody. There was no difference in AE rates in these subjects before and after the first titer increase to ≥1:160. The rate of infections during IGHy exposure was 2.99 per subject-year and did not increase during the studies. Annual infection rates were 3.02 in subjects <18 years and 2.98 in subjects ≥18 years. Conclusions: Long-term replacement therapy with IGHy was safe and effective in 83 pediatric and adult subjects with PIDD. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
02719142
Volume :
36
Issue :
6
Database :
Complementary Index
Journal :
Journal of Clinical Immunology
Publication Type :
Academic Journal
Accession number :
116747662
Full Text :
https://doi.org/10.1007/s10875-016-0298-x